Skip to main content
Erschienen in: Cancer and Metastasis Reviews 4/2016

08.12.2016

Current challenges of metastatic breast cancer

verfasst von: Bora Lim, Gabriel N. Hortobagyi

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Metastasis is one of the most characteristic yet problematic behaviors of cancer cells. Stage IV breast cancer accounts for a large portion of breast cancer-related morbidity and mortality. Despite early detection and improvement in survival owing to advancements in biomedical research and overall improvement of the health system, 6–10% of patients present with stage IV disease in the developed world, with a higher incidence noted elsewhere. Despite advances in biomedical research into cancer, up to 70–80% of patients with stage IV breast cancer die of cancer in 5 years, a disproportionally higher mortality compared with non-metastatic breast cancer. In this article, we review the incidence, survival, heterogeneity, current practice, and challenges in stage IV breast cancer, and we finish by noting new research initiatives to improve poor survival and suggesting future directions. By doing so, we hope to set the basis of future directions for both treating physicians and translational researchers to relieve the suffering of patients with stage IV breast cancer and improve the survival of patients with this dismal disease.
Literatur
3.
Zurück zum Zitat Walters, S., Maringe, C., Butler, J., Rachet, B., Barrett-Lee, P., Bergh, J., et al. (2013). Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. British Journal of Cancer, 108(5), 1195–1208. doi:10.1038/bjc.2013.6.PubMedPubMedCentralCrossRef Walters, S., Maringe, C., Butler, J., Rachet, B., Barrett-Lee, P., Bergh, J., et al. (2013). Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. British Journal of Cancer, 108(5), 1195–1208. doi:10.​1038/​bjc.​2013.​6.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: a Cancer Journal for Clinicians, 66(1), 7–30. doi:10.3322/caac.21332. Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: a Cancer Journal for Clinicians, 66(1), 7–30. doi:10.​3322/​caac.​21332.
7.
Zurück zum Zitat Di Meglio, A., Freedman, R. A., Lin, N. U., Barry, W. T., Metzger-Filho, O., Keating, N. L., et al. (2016). Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research and Treatment, 157(3), 587–596. doi:10.1007/s10549-016-3845-5.PubMedCrossRef Di Meglio, A., Freedman, R. A., Lin, N. U., Barry, W. T., Metzger-Filho, O., Keating, N. L., et al. (2016). Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research and Treatment, 157(3), 587–596. doi:10.​1007/​s10549-016-3845-5.PubMedCrossRef
9.
Zurück zum Zitat Adisa, A. O., Arowolo, O. A., Akinkuolie, A. A., Titiloye, N. A., Alatise, O. I., Lawal, O. O., et al. (2011). Metastatic breast cancer in a Nigerian tertiary hospital. African Health Sciences, 11(2), 279–284.PubMedPubMedCentral Adisa, A. O., Arowolo, O. A., Akinkuolie, A. A., Titiloye, N. A., Alatise, O. I., Lawal, O. O., et al. (2011). Metastatic breast cancer in a Nigerian tertiary hospital. African Health Sciences, 11(2), 279–284.PubMedPubMedCentral
10.
Zurück zum Zitat Iwasaki, H., & Suda, T. (2009). Cancer stem cells and their niche. Cancer Science, 100(7), 1166–1172 doi:CAS1177.PubMedCrossRef Iwasaki, H., & Suda, T. (2009). Cancer stem cells and their niche. Cancer Science, 100(7), 1166–1172 doi:CAS1177.PubMedCrossRef
12.
Zurück zum Zitat Legha, S. S., Buzdar, A. U., Smith, T. L., Hortobagyi, G. N., Swenerton, K. D., Blumenschein, G. R., et al. (1979). Complete remissions in metastatic breast cancer treated with combination drug therapy. Annals of Internal Medicine, 91(6), 847–852.PubMedCrossRef Legha, S. S., Buzdar, A. U., Smith, T. L., Hortobagyi, G. N., Swenerton, K. D., Blumenschein, G. R., et al. (1979). Complete remissions in metastatic breast cancer treated with combination drug therapy. Annals of Internal Medicine, 91(6), 847–852.PubMedCrossRef
13.
Zurück zum Zitat Nistico, C., Cuppone, F., Bria, E., Fornier, M., Giannarelli, D., Mottolese, M., et al. (2006). Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. Anti-Cancer Drugs, 17(10), 1193–1200. doi:10.1097/01.cad.0000231485.17063.d3.PubMedCrossRef Nistico, C., Cuppone, F., Bria, E., Fornier, M., Giannarelli, D., Mottolese, M., et al. (2006). Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. Anti-Cancer Drugs, 17(10), 1193–1200. doi:10.​1097/​01.​cad.​0000231485.​17063.​d3.PubMedCrossRef
14.
Zurück zum Zitat Chang, F. (2003). Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (review). International Journal of Oncology, 22(3), 469–480.PubMed Chang, F. (2003). Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (review). International Journal of Oncology, 22(3), 469–480.PubMed
15.
Zurück zum Zitat Stanford, J. L., Szklo, M., & Brinton, L. A. (1986). Estrogen receptors and breast cancer. Epidemiologic Reviews, 8, 42–59.PubMed Stanford, J. L., Szklo, M., & Brinton, L. A. (1986). Estrogen receptors and breast cancer. Epidemiologic Reviews, 8, 42–59.PubMed
16.
Zurück zum Zitat Koboldt, D. C., Fulton, R., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., McMichael, J. F., Fulton, L. L., et al. (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490(7418), 61–70. doi:10.1038/nature11412.CrossRef Koboldt, D. C., Fulton, R., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., McMichael, J. F., Fulton, L. L., et al. (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490(7418), 61–70. doi:10.​1038/​nature11412.CrossRef
17.
Zurück zum Zitat Kimbung, S., Kovacs, A., Danielsson, A., Bendahl, P. O., Lovgren, K., Frostvik Stolt, M., et al. (2015). Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget, 6(32), 33306–33318. doi:10.18632/oncotarget.5089.PubMedPubMedCentral Kimbung, S., Kovacs, A., Danielsson, A., Bendahl, P. O., Lovgren, K., Frostvik Stolt, M., et al. (2015). Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget, 6(32), 33306–33318. doi:10.​18632/​oncotarget.​5089.PubMedPubMedCentral
18.
Zurück zum Zitat Engstrom, M. J., Opdahl, S., Hagen, A. I., Romundstad, P. R., Akslen, L. A., Haugen, O. A., et al. (2013). Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Research and Treatment, 140(3), 463–473. doi:10.1007/s10549-013-2647-2.PubMedPubMedCentralCrossRef Engstrom, M. J., Opdahl, S., Hagen, A. I., Romundstad, P. R., Akslen, L. A., Haugen, O. A., et al. (2013). Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Research and Treatment, 140(3), 463–473. doi:10.​1007/​s10549-013-2647-2.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat De Vita, F., Giuliani, F., Silvestris, N., Catalano, G., Ciardiello, F., & Orditura, M. (2010). Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treatment Reviews, 36(Suppl 3), S11–S15. doi:10.1016/S0305-7372(10)70014-1.PubMedCrossRef De Vita, F., Giuliani, F., Silvestris, N., Catalano, G., Ciardiello, F., & Orditura, M. (2010). Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treatment Reviews, 36(Suppl 3), S11–S15. doi:10.​1016/​S0305-7372(10)70014-1.PubMedCrossRef
22.
Zurück zum Zitat van’t Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871), 530–536. doi:10.1038/415530a.CrossRef van’t Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871), 530–536. doi:10.​1038/​415530a.CrossRef
23.
Zurück zum Zitat Calemma, R., Ottaiano, A., & Trotta, A. M. E. A. (2012). Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. Journal of Translational Medicine, 10, 232. doi:10.1186/1479-5876-10-232.PubMedPubMedCentralCrossRef Calemma, R., Ottaiano, A., & Trotta, A. M. E. A. (2012). Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. Journal of Translational Medicine, 10, 232. doi:10.​1186/​1479-5876-10-232.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Deng, Y., Lin, Y., & Wu, X. (2002). TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes & Development, 16(1), 33–45. doi:10.1101/gad.949602.CrossRef Deng, Y., Lin, Y., & Wu, X. (2002). TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes & Development, 16(1), 33–45. doi:10.​1101/​gad.​949602.CrossRef
25.
Zurück zum Zitat Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V., et al. (1998). Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. Journal of Clinical Oncology, 16(10), 3439–3460.PubMed Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V., et al. (1998). Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. Journal of Clinical Oncology, 16(10), 3439–3460.PubMed
26.
Zurück zum Zitat Kaufmann, M., Jonat, W., Kleeberg, U., Eiermann, W., Jänicke, F., Hilfrich, J., et al. (1989). Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex trial group. Journal of Clinical Oncology, 7(8), 1113–1119.PubMed Kaufmann, M., Jonat, W., Kleeberg, U., Eiermann, W., Jänicke, F., Hilfrich, J., et al. (1989). Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex trial group. Journal of Clinical Oncology, 7(8), 1113–1119.PubMed
27.
Zurück zum Zitat Grosse-Wilde, A., Voloshanenko, O., Bailey, S. L., Longton, G. M., Schaefer, U., Csernok, A. I., et al. (2008). TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. The Journal of Clinical Investigation, 118(1), 100–110. doi:10.1172/jci33061.PubMedCrossRef Grosse-Wilde, A., Voloshanenko, O., Bailey, S. L., Longton, G. M., Schaefer, U., Csernok, A. I., et al. (2008). TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. The Journal of Clinical Investigation, 118(1), 100–110. doi:10.​1172/​jci33061.PubMedCrossRef
28.
Zurück zum Zitat Finnberg, N., Klein-Szanto, A. J., & El-Deiry, W. S. (2008). TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. The Journal of Clinical Investigation, 118(1), 111–123. doi:10.1172/jci29900.PubMedCrossRef Finnberg, N., Klein-Szanto, A. J., & El-Deiry, W. S. (2008). TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. The Journal of Clinical Investigation, 118(1), 111–123. doi:10.​1172/​jci29900.PubMedCrossRef
29.
Zurück zum Zitat MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N., Kennedy, D. B. J., et al. (2005). Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death and Differentiation, 12(7), 773–782. doi:10.1038/sj.cdd.4401649.PubMedCrossRef MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N., Kennedy, D. B. J., et al. (2005). Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death and Differentiation, 12(7), 773–782. doi:10.​1038/​sj.​cdd.​4401649.PubMedCrossRef
30.
Zurück zum Zitat MacFarlane, M., Ahmad, M., Srinivasula, S., Fernandes-Alnemri, T., Cohen, G., Alnemri, E., et al. (1997). Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. The Journal of Biological Chemistry, 272, 25417–25420. doi:10.1074/jbc.272.41.25417.PubMedCrossRef MacFarlane, M., Ahmad, M., Srinivasula, S., Fernandes-Alnemri, T., Cohen, G., Alnemri, E., et al. (1997). Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. The Journal of Biological Chemistry, 272, 25417–25420. doi:10.​1074/​jbc.​272.​41.​25417.PubMedCrossRef
32.
Zurück zum Zitat Manzo, F., Miceli, M., Conte, M., De Bellis, F., Carafa, V., Franci, G., et al. (2009). TNF-related apoptosis-inducing ligand. Signalling of a ‘Smart’ Molecule, 41(3), 460–466. doi:10.1016/j.biocel.2007.12.012. Manzo, F., Miceli, M., Conte, M., De Bellis, F., Carafa, V., Franci, G., et al. (2009). TNF-related apoptosis-inducing ligand. Signalling of a ‘Smart’ Molecule, 41(3), 460–466. doi:10.​1016/​j.​biocel.​2007.​12.​012.
34.
Zurück zum Zitat Jin, Z., Dicker, D. T., & El-Deiry, W. S. (2002). Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle, 1(1), 82–89.PubMedCrossRef Jin, Z., Dicker, D. T., & El-Deiry, W. S. (2002). Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle, 1(1), 82–89.PubMedCrossRef
35.
Zurück zum Zitat Keating, J., Tsoli, M., Hallahan, A., Ingram, W., Haber, M., Ziegler, D., et al. (2012). Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in Medulloblastoma. Molecular Cancer Therapeutics, 11(10), 1–10. doi:10.1158/1535-7163.MCT-12-0352. Keating, J., Tsoli, M., Hallahan, A., Ingram, W., Haber, M., Ziegler, D., et al. (2012). Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in Medulloblastoma. Molecular Cancer Therapeutics, 11(10), 1–10. doi:10.​1158/​1535-7163.​MCT-12-0352.
36.
Zurück zum Zitat Keane, M. M., Rubinstein, Y., Cuello, M., Ettenberg, S. A., Banerjee, P., Nau, M. M., et al. (2000). Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Research and Treatment, 64(2), 211–219.PubMedCrossRef Keane, M. M., Rubinstein, Y., Cuello, M., Ettenberg, S. A., Banerjee, P., Nau, M. M., et al. (2000). Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Research and Treatment, 64(2), 211–219.PubMedCrossRef
37.
Zurück zum Zitat Karacay, B., Sanlioglu, S., Griffith, T. S., Griffith, T. S., Griffith, T. S., Griffith, T. S., et al. (2004). Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Therapy, 11(10), 681–690. doi:10.1038/sj.cgt.7700749.PubMedCrossRef Karacay, B., Sanlioglu, S., Griffith, T. S., Griffith, T. S., Griffith, T. S., Griffith, T. S., et al. (2004). Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Therapy, 11(10), 681–690. doi:10.​1038/​sj.​cgt.​7700749.PubMedCrossRef
38.
Zurück zum Zitat Blair, J. M., Zhou, H., Seibel, M. J., & Dunstan, C. R. (2006). Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Reviews Clinical Oncology, 3(1), 41–49. doi:10.1038/ncponc0381.CrossRef Blair, J. M., Zhou, H., Seibel, M. J., & Dunstan, C. R. (2006). Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Reviews Clinical Oncology, 3(1), 41–49. doi:10.​1038/​ncponc0381.CrossRef
39.
Zurück zum Zitat Kelly, M., Hoel, B., & Voelkel-Johnson, C. (2002). Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biology & Therapy, 1(5), 520–527 doi:05240288.CrossRef Kelly, M., Hoel, B., & Voelkel-Johnson, C. (2002). Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biology & Therapy, 1(5), 520–527 doi:05240288.CrossRef
41.
Zurück zum Zitat Kajiwara, K., Saito, A., Ogata, S., & Tanihara, M. (2004). Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively. Biochimica et Biophysica Acta, 1699(1–2), 131–137. doi:10.1016/j.bbapap.2004.02.016.PubMedCrossRef Kajiwara, K., Saito, A., Ogata, S., & Tanihara, M. (2004). Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively. Biochimica et Biophysica Acta, 1699(1–2), 131–137. doi:10.​1016/​j.​bbapap.​2004.​02.​016.PubMedCrossRef
42.
Zurück zum Zitat Plastaras, J. P., Dorsey, J. F., Carroll, K., Kim, S. H., Birnbaum, M. J., & El-Deiry, W. S. (2008). Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biology & Therapy, 7(12), 2047–2053.CrossRef Plastaras, J. P., Dorsey, J. F., Carroll, K., Kim, S. H., Birnbaum, M. J., & El-Deiry, W. S. (2008). Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biology & Therapy, 7(12), 2047–2053.CrossRef
43.
Zurück zum Zitat Pitti, R. M., Marsters, S. A., Ruppert, S., Ruppert, S., Ruppert, S., Ruppert, S., et al. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of Biological Chemistry, 271(22), 12687–12690.PubMedCrossRef Pitti, R. M., Marsters, S. A., Ruppert, S., Ruppert, S., Ruppert, S., Ruppert, S., et al. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of Biological Chemistry, 271(22), 12687–12690.PubMedCrossRef
44.
Zurück zum Zitat Phipps, A. I., Buchanan, D. D., Makar, K. W., Burnett-Hartman, A. N., Coghill, A. E., Passarelli, M. N., et al. (2012). BRAF mutation status and survival after colorectal cancer diagnosis according to. Cancer Epidemiology, Biomarkers & Prevention, 21(10), 1792–1798. doi:10.1158/1055-9965.epi-12-0674.CrossRef Phipps, A. I., Buchanan, D. D., Makar, K. W., Burnett-Hartman, A. N., Coghill, A. E., Passarelli, M. N., et al. (2012). BRAF mutation status and survival after colorectal cancer diagnosis according to. Cancer Epidemiology, Biomarkers & Prevention, 21(10), 1792–1798. doi:10.​1158/​1055-9965.​epi-12-0674.CrossRef
45.
Zurück zum Zitat Ravi, R., Bedi, G. C., Engstrom, L. W., Ravi, R., Bedi, G. C., Engstrom, L. W., et al. (2001). Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nature Cell Biology, 3(4), 409–416. doi:10.1038/35070096.PubMedCrossRef Ravi, R., Bedi, G. C., Engstrom, L. W., Ravi, R., Bedi, G. C., Engstrom, L. W., et al. (2001). Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nature Cell Biology, 3(4), 409–416. doi:10.​1038/​35070096.PubMedCrossRef
46.
Zurück zum Zitat Prasad, S., Yadav, V. R., Kannappan, R., Kannappan, R., Kannappan, R., Kannappan, R., et al. (2011). Ursolic acid, a Pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors. Journ of Biological Chemistry, 286, 5546–5557. doi:10.1074/jbc.M110.183699.CrossRef Prasad, S., Yadav, V. R., Kannappan, R., Kannappan, R., Kannappan, R., Kannappan, R., et al. (2011). Ursolic acid, a Pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors. Journ of Biological Chemistry, 286, 5546–5557. doi:10.​1074/​jbc.​M110.​183699.CrossRef
48.
Zurück zum Zitat Rimawi, M., Mayer, I., Forero, A., Nanda, R., Goetz, M., Rodriguez, A., et al. (2013). Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006. doi:10.1200/JCO.2012.44.8027. Rimawi, M., Mayer, I., Forero, A., Nanda, R., Goetz, M., Rodriguez, A., et al. (2013). Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006. doi:10.​1200/​JCO.​2012.​44.​8027.
49.
Zurück zum Zitat Robidoux, A., Tang, G., Rastogi, P., Geyer Jr., C. E., Azar, C. A., Atkins, J. N., et al. (2013). Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology, 14(12), 1183–1192. doi:10.1016/s1470-2045(13)70411-x.PubMedCrossRef Robidoux, A., Tang, G., Rastogi, P., Geyer Jr., C. E., Azar, C. A., Atkins, J. N., et al. (2013). Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology, 14(12), 1183–1192. doi:10.​1016/​s1470-2045(13)70411-x.PubMedCrossRef
51.
Zurück zum Zitat Assersohn, L., Salter, J., Powles, T. J., A’Hern, R., Makris, A., Gregory, R. K., et al. (2003). Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Research and Treatment, 82(2), 113–123. doi:10.1023/B:BREA.0000003968.45511.3f.PubMedCrossRef Assersohn, L., Salter, J., Powles, T. J., A’Hern, R., Makris, A., Gregory, R. K., et al. (2003). Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Research and Treatment, 82(2), 113–123. doi:10.​1023/​B:​BREA.​0000003968.​45511.​3f.PubMedCrossRef
52.
Zurück zum Zitat Crump, M., Sawka, C. A., DeBoer, G., Buchanan, R. B., Ingle, J. N., Forbes, J., et al. (1997). An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Research and Treatment, 44(3), 201–210.PubMedCrossRef Crump, M., Sawka, C. A., DeBoer, G., Buchanan, R. B., Ingle, J. N., Forbes, J., et al. (1997). An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Research and Treatment, 44(3), 201–210.PubMedCrossRef
53.
Zurück zum Zitat Yan, S., Li, K., Jiao, X., & Zou, H. (2015). Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. Onco Targets and Therapy, 8, 1433–1441. doi:10.2147/ott.s86817.CrossRef Yan, S., Li, K., Jiao, X., & Zou, H. (2015). Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. Onco Targets and Therapy, 8, 1433–1441. doi:10.​2147/​ott.​s86817.CrossRef
54.
Zurück zum Zitat Mauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. (2006). Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Journal of the National Cancer Institute, 98(18), 1285–1291. doi:10.1093/jnci/djj357.PubMedCrossRef Mauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. (2006). Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Journal of the National Cancer Institute, 98(18), 1285–1291. doi:10.​1093/​jnci/​djj357.PubMedCrossRef
55.
Zurück zum Zitat Ellis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiowka, M., Hewson, N., et al. (2015). Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. Journal of Clinical Oncology, 33(32), 3781–3787. doi:10.1200/jco.2015.61.5831.PubMedPubMedCentralCrossRef Ellis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiowka, M., Hewson, N., et al. (2015). Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. Journal of Clinical Oncology, 33(32), 3781–3787. doi:10.​1200/​jco.​2015.​61.​5831.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Dauvois, S., White, R., & Parker, M. G. (1993). The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science, 106(Pt 4), 1377–1388.PubMed Dauvois, S., White, R., & Parker, M. G. (1993). The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science, 106(Pt 4), 1377–1388.PubMed
57.
Zurück zum Zitat Robertson, J. F., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., et al. (2009). Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. Journal of Clinical Oncology, 27(27), 4530–4535. doi:10.1200/jco.2008.21.1136.PubMedCrossRef Robertson, J. F., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., et al. (2009). Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. Journal of Clinical Oncology, 27(27), 4530–4535. doi:10.​1200/​jco.​2008.​21.​1136.PubMedCrossRef
58.
59.
Zurück zum Zitat Pang, B., Cheng, S., Sun, S. P., An, C., Liu, Z. Y., Feng, X., et al. (2014). Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Scientific Reports, 4, 6255. doi:10.1038/srep06255.PubMedPubMedCentralCrossRef Pang, B., Cheng, S., Sun, S. P., An, C., Liu, Z. Y., Feng, X., et al. (2014). Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Scientific Reports, 4, 6255. doi:10.​1038/​srep06255.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., et al. (2011). Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Research, 13(2), R21. doi:10.1186/bcr2833.PubMedPubMedCentralCrossRef Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., et al. (2011). Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Research, 13(2), R21. doi:10.​1186/​bcr2833.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., et al. (2009). Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology, 27(16), 2630–2637. doi:10.1200/jco.2008.18.8391.PubMedCrossRef Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., et al. (2009). Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology, 27(16), 2630–2637. doi:10.​1200/​jco.​2008.​18.​8391.PubMedCrossRef
62.
Zurück zum Zitat Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., et al. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet Oncology, 16(1), 25–35. doi:10.1016/s1470-2045(14)71159-3.PubMedCrossRef Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., et al. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet Oncology, 16(1), 25–35. doi:10.​1016/​s1470-2045(14)71159-3.PubMedCrossRef
63.
Zurück zum Zitat Finn, R.S., Martin, M., Rugo, H.S., Jones, S.E., Im, S-A., Gelmon, K.A., et al. (2016). PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol, suppl; abstr 507. Finn, R.S., Martin, M., Rugo, H.S., Jones, S.E., Im, S-A., Gelmon, K.A., et al. (2016). PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol, suppl; abstr 507.
64.
Zurück zum Zitat Dickler, M., Tolaney, S., Rugo, H., Cortes, J., Dieras, V., Patt, D., et al. (2016). MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy. ASCO annual meeting. Dickler, M., Tolaney, S., Rugo, H., Cortes, J., Dieras, V., Patt, D., et al. (2016). MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy. ASCO annual meeting.
65.
Zurück zum Zitat Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., et al. (2013). Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. Journal of Clinical Oncology, 31(17), 2128–2135. doi:10.1200/jco.2012.43.7251.PubMedPubMedCentralCrossRef Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., et al. (2013). Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. Journal of Clinical Oncology, 31(17), 2128–2135. doi:10.​1200/​jco.​2012.​43.​7251.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Kornblith, A. B., Hollis, D. R., Zuckerman, E., Lyss, A. P., Canellos, G. P., Cooper, M. R., et al. (1993). Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The cancer and leukemia group B. Journal of Clinical Oncology, 11(11), 2081–2089.PubMed Kornblith, A. B., Hollis, D. R., Zuckerman, E., Lyss, A. P., Canellos, G. P., Cooper, M. R., et al. (1993). Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The cancer and leukemia group B. Journal of Clinical Oncology, 11(11), 2081–2089.PubMed
67.
Zurück zum Zitat Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., et al. (2014). Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. [research article]. Breast Cancer Research, 16(1). Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., et al. (2014). Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. [research article]. Breast Cancer Research, 16(1).
68.
69.
Zurück zum Zitat Kamal, A. H., Camacho, F., Anderson, R., Wei, W., Balkrishnan, R., & Kimmick, G. (2012). Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment, 134(1), 371–378. doi:10.1007/s10549-012-2037-1.PubMedCrossRef Kamal, A. H., Camacho, F., Anderson, R., Wei, W., Balkrishnan, R., & Kimmick, G. (2012). Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment, 134(1), 371–378. doi:10.​1007/​s10549-012-2037-1.PubMedCrossRef
70.
Zurück zum Zitat Liu, M., Mo, Q. G., Wei, C. Y., Qin, Q. H., Huang, Z., & He, J. (2013). Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncology Letters, 5(3), 983–991. doi:10.3892/ol.2012.1093.PubMed Liu, M., Mo, Q. G., Wei, C. Y., Qin, Q. H., Huang, Z., & He, J. (2013). Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncology Letters, 5(3), 983–991. doi:10.​3892/​ol.​2012.​1093.PubMed
71.
Zurück zum Zitat Chandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D., et al. (2016). Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncology. doi:10.1001/jamaoncol.2016.1279.PubMed Chandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D., et al. (2016). Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncology. doi:10.​1001/​jamaoncol.​2016.​1279.PubMed
72.
Zurück zum Zitat Andersson, M., Lidbrink, E., Bjerre, K., et al. (2011). Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: the HERNATA study. Journal of Clinical Oncology. doi:10.1200/JCO.2010.30.8213. Andersson, M., Lidbrink, E., Bjerre, K., et al. (2011). Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: the HERNATA study. Journal of Clinical Oncology. doi:10.​1200/​JCO.​2010.​30.​8213.
73.
Zurück zum Zitat Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute, 93(24), 1852–1857.PubMedCrossRef Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute, 93(24), 1852–1857.PubMedCrossRef
74.
Zurück zum Zitat Ritter, C. A., Bianco, R., Dugger, T., Forbes, J., Qu, S., Rinehart, C., et al. (2004). Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. International Journal of Clinical Pharmacology and Therapeutics, 42(11), 642–643.PubMedCrossRef Ritter, C. A., Bianco, R., Dugger, T., Forbes, J., Qu, S., Rinehart, C., et al. (2004). Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. International Journal of Clinical Pharmacology and Therapeutics, 42(11), 642–643.PubMedCrossRef
75.
Zurück zum Zitat Shattuck, D. L., Miller, J. K., Carraway 3rd, K. L., & Sweeney, C. (2008). Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research, 68(5), 1471–1477 doi:68/5/1471.PubMedCrossRef Shattuck, D. L., Miller, J. K., Carraway 3rd, K. L., & Sweeney, C. (2008). Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research, 68(5), 1471–1477 doi:68/5/1471.PubMedCrossRef
76.
Zurück zum Zitat Rexer, B. N., & Arteaga, C. L. (2012). Intrinsic and acquired resistance to HER2-targeted therapies in HER2 Gene-amplified breast cancer: mechanisms and clinical implications. Critical Reviews in Oncogenesis, 17(1), 1–16.PubMedPubMedCentralCrossRef Rexer, B. N., & Arteaga, C. L. (2012). Intrinsic and acquired resistance to HER2-targeted therapies in HER2 Gene-amplified breast cancer: mechanisms and clinical implications. Critical Reviews in Oncogenesis, 17(1), 1–16.PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Scaltriti, M., Rojo, F., Ocaña, A., Anido, J., Guzman, M., Cortes, J., et al. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. JNCI, 99(8). doi:10.1093/jnci/djk134. Scaltriti, M., Rojo, F., Ocaña, A., Anido, J., Guzman, M., Cortes, J., et al. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. JNCI, 99(8). doi:10.​1093/​jnci/​djk134.
79.
Zurück zum Zitat Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009). Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Research, 69(24), 9330–9336. doi:10.1158/0008-5472.CAN-08-4597.PubMedCrossRef Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009). Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Research, 69(24), 9330–9336. doi:10.​1158/​0008-5472.​CAN-08-4597.PubMedCrossRef
80.
Zurück zum Zitat Guan, Z., Xu, B., DeSilvio, M. L., Shen, Z., Arpornwirat, W., Tong, Z., et al. (2013). Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 31(16), 1947–1953. doi:10.1200/jco.2011.40.5241.PubMedCrossRef Guan, Z., Xu, B., DeSilvio, M. L., Shen, Z., Arpornwirat, W., Tong, Z., et al. (2013). Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 31(16), 1947–1953. doi:10.​1200/​jco.​2011.​40.​5241.PubMedCrossRef
81.
Zurück zum Zitat Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., et al. (2012). Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. Journal of Clinical Oncology, 30(21), 2585–2592. doi:10.1200/jco.2011.35.6725.PubMedCrossRef Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., et al. (2012). Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. Journal of Clinical Oncology, 30(21), 2585–2592. doi:10.​1200/​jco.​2011.​35.​6725.PubMedCrossRef
82.
Zurück zum Zitat Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., et al. (2010). Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology, 28(7), 1124–1130. doi:10.1200/jco.2008.21.4437.PubMedCrossRef Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., et al. (2010). Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology, 28(7), 1124–1130. doi:10.​1200/​jco.​2008.​21.​4437.PubMedCrossRef
83.
Zurück zum Zitat Krop, I. E., Kim, S. B., Gonzalez-Martin, A., LoRusso, P. M., Ferrero, J. M., Smitt, M., et al. (2014). Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet Oncology, 15(7), 689–699. doi:10.1016/s1470-2045(14)70178-0.PubMedCrossRef Krop, I. E., Kim, S. B., Gonzalez-Martin, A., LoRusso, P. M., Ferrero, J. M., Smitt, M., et al. (2014). Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet Oncology, 15(7), 689–699. doi:10.​1016/​s1470-2045(14)70178-0.PubMedCrossRef
84.
Zurück zum Zitat Sparano, J. A., Makhson, A. N., Semiglazov, V. F., Tjulandin, S. A., Balashova, O. I., Bondarenko, I. N., et al. (2009). Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. Journal of Clinical Oncology, 27(27), 4522–4529. doi:10.1200/jco.2008.20.5013.PubMedCrossRef Sparano, J. A., Makhson, A. N., Semiglazov, V. F., Tjulandin, S. A., Balashova, O. I., Bondarenko, I. N., et al. (2009). Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. Journal of Clinical Oncology, 27(27), 4522–4529. doi:10.​1200/​jco.​2008.​20.​5013.PubMedCrossRef
85.
Zurück zum Zitat Mauri, D., Kamposioras, K., Tsali, L., Bristianou, M., Valachis, A., Karathanasi, I., et al. (2010). Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treatment Reviews, 36(1), 69–74. doi:10.1016/j.ctrv.2009.10.006.PubMedCrossRef Mauri, D., Kamposioras, K., Tsali, L., Bristianou, M., Valachis, A., Karathanasi, I., et al. (2010). Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treatment Reviews, 36(1), 69–74. doi:10.​1016/​j.​ctrv.​2009.​10.​006.PubMedCrossRef
86.
Zurück zum Zitat O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J. P., Cervantes, G., et al. (2002). Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology, 20(12), 2812–2823.PubMedCrossRef O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J. P., Cervantes, G., et al. (2002). Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology, 20(12), 2812–2823.PubMedCrossRef
87.
Zurück zum Zitat Valero, V., Vrdoljak, E., Xu, B., Thomas, E., Gomez, H., Manikhas, A., et al. (2012). Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clinical Breast Cancer, 12(4), 240–246. doi:10.1016/j.clbc.2012.03.013.PubMedCrossRef Valero, V., Vrdoljak, E., Xu, B., Thomas, E., Gomez, H., Manikhas, A., et al. (2012). Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clinical Breast Cancer, 12(4), 240–246. doi:10.​1016/​j.​clbc.​2012.​03.​013.PubMedCrossRef
89.
Zurück zum Zitat de Ruijter, T., Veeck, J., de Hoon, J., van Engeland, M., & Tjan-Heijnen, V. (2011). Characteristics of triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 137(2), 183–192. doi:10.1007/s00432-010-0957-x.PubMedCrossRef de Ruijter, T., Veeck, J., de Hoon, J., van Engeland, M., & Tjan-Heijnen, V. (2011). Characteristics of triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 137(2), 183–192. doi:10.​1007/​s00432-010-0957-x.PubMedCrossRef
90.
Zurück zum Zitat Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., et al. (2009). Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clinical Breast Cancer, 9(1), 29–33. doi:10.3816/CBC.2009.n.005.PubMedCrossRef Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., et al. (2009). Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clinical Breast Cancer, 9(1), 29–33. doi:10.​3816/​CBC.​2009.​n.​005.PubMedCrossRef
91.
Zurück zum Zitat Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research, 13(15 Pt 1), 4429–4434. doi:10.1158/1078-0432.ccr-06-3045.PubMedCrossRef Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research, 13(15 Pt 1), 4429–4434. doi:10.​1158/​1078-0432.​ccr-06-3045.PubMedCrossRef
93.
Zurück zum Zitat Staudacher, L., Cottu, P. H., Dieras, V., Vincent-Salomon, A., Guilhaume, M. N., Escalup, L., et al. (2011). Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Annals of Oncology, 22(4), 848–856. doi:10.1093/annonc/mdq461.PubMedCrossRef Staudacher, L., Cottu, P. H., Dieras, V., Vincent-Salomon, A., Guilhaume, M. N., Escalup, L., et al. (2011). Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Annals of Oncology, 22(4), 848–856. doi:10.​1093/​annonc/​mdq461.PubMedCrossRef
96.
Zurück zum Zitat Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., et al. (2013). Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31(7), 860–867. doi:10.1200/jco.2011.41.0902.PubMedCrossRef Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., et al. (2013). Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31(7), 860–867. doi:10.​1200/​jco.​2011.​41.​0902.PubMedCrossRef
98.
Zurück zum Zitat Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation, 121(7), 2750–2767. doi:10.1172/JCI45014.PubMedPubMedCentralCrossRef Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation, 121(7), 2750–2767. doi:10.​1172/​JCI45014.PubMedPubMedCentralCrossRef
99.
Zurück zum Zitat Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., et al. (2013). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical Cancer Research, 19(19), 5533–5540. doi:10.1158/1078-0432.CCR-13-0799.PubMedCrossRef Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., et al. (2013). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical Cancer Research, 19(19), 5533–5540. doi:10.​1158/​1078-0432.​CCR-13-0799.PubMedCrossRef
101.
Zurück zum Zitat Stone, P., Richardson, A., Ream, E., Smith, A. G., Kerr, D. J., & Kearney, N. (2000). Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Annals of Oncology, 11(8), 971–975.PubMedCrossRef Stone, P., Richardson, A., Ream, E., Smith, A. G., Kerr, D. J., & Kearney, N. (2000). Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Annals of Oncology, 11(8), 971–975.PubMedCrossRef
102.
Zurück zum Zitat Park, Y. H., Jung, K. H., Im, S. A., Sohn, J. H., Ro, J., Ahn, J. H., et al. (2013). Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology, 31(14), 1732–1739. doi:10.1200/jco.2012.45.2490.PubMedCrossRef Park, Y. H., Jung, K. H., Im, S. A., Sohn, J. H., Ro, J., Ahn, J. H., et al. (2013). Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology, 31(14), 1732–1739. doi:10.​1200/​jco.​2012.​45.​2490.PubMedCrossRef
103.
105.
Zurück zum Zitat Andre, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., et al. (2014). Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). The Lancet Oncology, 15(3), 267–274. doi:10.1016/S1470-2045(13)70611-9.PubMedCrossRef Andre, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., et al. (2014). Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). The Lancet Oncology, 15(3), 267–274. doi:10.​1016/​S1470-2045(13)70611-9.PubMedCrossRef
Metadaten
Titel
Current challenges of metastatic breast cancer
verfasst von
Bora Lim
Gabriel N. Hortobagyi
Publikationsdatum
08.12.2016
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 4/2016
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-016-9636-y

Weitere Artikel der Ausgabe 4/2016

Cancer and Metastasis Reviews 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.